Sahajanand Medical Technologies IPO

SEBI has approved the Initial Public Offer (IPO) of Sahajanand Medical Technologies Ltd. on 17 November 2025. The company will now proceed with the next steps for launching the IPO, depending on market conditions and other required approvals. The SEBI approval remains valid for 12 months.

This IPO is a Book-Build Issue consisting entirely of an Offer for Sale (OFS) of up to 2.76 crore equity shares. There is no fresh issue component, and hence the company will not receive any proceeds from the IPO.

The equity shares are proposed to be listed on BSE and NSE.
Motilal Oswal Investment Advisors Ltd. is the Book Running Lead Manager and MUFG Intime India Pvt. Ltd. is the Registrar of the issue.
IPO dates, price band, and lot size will be updated once announced.

👉 GMP | Reviews | Subscription | Allotment

👉 Chanakya Grey Market Intelligence – 8 PM Edition | News Crux | 

👉 Power Calls | Breakout Stocks | Coffee Can Portfolio | 

IPO Details

IPO Reservation

Special Bidding Limits

DRHP Status

Promoter Holding

Promoters: Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust

About Sahajanand Medical Technologies Ltd.

Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a leading medical device manufacturer specializing in Class III and Class C/D medical devices, with a strong focus on vascular and structural heart interventions.

The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer — Infinnium.

Their portfolio includes:
• Vascular Intervention (VI): Coronary stents, balloons
• Structural Heart (SH): TAVI valves, Occluders
• Others: Renal stents, peripheral DCBs, and select traded devices

Sahajanand operates two R&D centres (India & Thailand) with 102 R&D professionals, and holds 102 granted patents, 71 pending applications, and five design registrations in India.

Key brands include Supraflex Cruz (DES), Hydra (TAVI), and Cocoon (Occluders) — supported by 72 clinical studies and commercialized in 76+ countries.

Global presence includes:
• Direct operations in Germany, Spain, France, UK
• Hybrid model in India (serving major hospitals including Narayana Hrudayalaya)
• Distributor-led operations in markets such as Italy

As of March 31, 2025, the company employed:
• 1,458 full-time staff
• 24 consultants
• 818 contract workers

Financial Snapshot (Rs. Crore) – Restated Consolidated

Key Performance Indicators

Objects of the Issue

Company Contact

Sahajanand Medical Technologies Ltd.
Sahajanand Estate, Wakharia Wadi,
Nr. Dabholi Char Rasta, Nani Ved Road,
Surat, Gujarat – 395004
Phone: 022-49564000
Email: investors.grievance@smt.in
Website: www.smtpl.com

Registrar

MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: sahajanandmedical.ipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html

Lead Managers

• Motilal Oswal Investment Advisors Ltd.
• Avendus Capital Pvt. Ltd.
• HSBC Securities & Capital Markets (India) Pvt. Ltd.
• Nuvama Wealth Management Ltd.